




CORRECTION

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Thomas Decaens , Carlo Barone, Eric Assenat, Martin Wermke, Angelica Fasolo, Philippe Merle, Jean-Frédéric Blanc, Véronique Grando, Angelo Iacobellis, Erica Villa, Joerg Trojan, Josef Straub, Rolf Bruns, Karin Berghoff, Juergen Scheele, Eric Raymond and Sandrine Faivre

British Journal of Cancer (2021) 125:465; <https://doi.org/10.1038/s41416-021-01403-z>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-021-01334-9>, published online 6 April 2021

The original version of this article unfortunately contained a mistake. Due to a typesetting error ‘sorafenib pretreated’ was changed to ‘sorafenibpretreated’ throughout the article. The correct spelling is ‘sorafenib pretreated’. There were also minor errors in Fig. 1 and Fig. 3. The original article has been corrected.

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

© The Author(s) 2021